SSTR2 and neoplasm: The few critical factors, which influence the choice of the first modality in the setting of metastatic pNET are tumor biology, reflected by the grading, and SSTR density— SSTR2 density mostly drives the susceptibility of pNET to somatostatin receptor therapies.